1 / 25

Immune Sensing of Latent Cytomegalovirus Reactivation: Impact on Immune Senescence?

Institute for Virology. Immune Sensing of Latent Cytomegalovirus Reactivation: Impact on Immune Senescence?. Molecular Virology Lab. Immunology Lab. Cytomegalic Inclusion Disease (CID): a disease of the immunocompromised. Congenital infection (in the US) Cases per annum: 40,000

harsha
Download Presentation

Immune Sensing of Latent Cytomegalovirus Reactivation: Impact on Immune Senescence?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Institute for Virology Immune Sensing of Latent Cytomegalovirus Reactivation: Impact on Immune Senescence? Molecular Virology Lab Immunology Lab

  2. Cytomegalic Inclusion Disease (CID): a disease of the immunocompromised Congenital infection (in the US) Cases per annum: 40,000 Asymptomatic at birth: 36,000 5,400 Neurol. sequelae Symptomatic at birth: 4,000 3,600 Neurol. sequelae 400 Fatal cases Transplantation-associated (in the US) Cases per annum: 2,800 Moderate disease: 1,200 Severe disease: 1,600 160 Fatal cases IOM study: Vaccines for the 21st century CMV vaccine is 1 out of 7 ranked in level 1 out of 26 candidate vaccines included in the study Annual gain of 18,000 - 70,000 QALYs Annual saving to the health system US $ 1.1 billion - 4.0 billion Courtesy of G.Jahn Institute of Medical Virology Tuebingen Jahn et al., Dtsch. Med. Wochenschrift, 1988

  3. Immune senescence: A new indication for a CMV vaccine? People aged 65 and older in the US ~ 40 million Carriers of latent CMV ~ 30 million

  4. ~ Immune surveillance of CMV in the murine BMT model 6 Gy mCMV BMC BALB/c BALB/c Recipient Donor Lungs Latency Acute phase Virus CD8 T cells 1 5 10 months Holtappels et al., JVI, 1998 Podlech et al., JVI, 2000

  5. ~ Control of acute CMV infection in the lungs 6 Gy mCMV Inflammatory focus BMC BALB/c BALB/c Recipient Donor Lungs Latency Acute phase Virus CD8 T cells 1 5 10 months Red staining of intranuclear IE1 protein Black staining of CD8 T cells Podlech et al., JVl, 2000

  6. ~ Control of acute CMV infection in the lungs Effector CD8 T cells • Activated phenotype CD62Llow • Secrete IFN-g • Lyse infected target cells Protection upon adoptive transfer mCMV 6 Gy BALB/c Recipient Podlech et al., JVI, 2000 Holtappels et al., JVI, 1998; 2000

  7. CD8 T cell ~ ~ Persistence of protective CD8 T cell infiltrates during latency Effector-memory CD8 T cells 6 Gy mCMV • Activated phenotype CD62Llow • Secrete IFN-g • Protect upon adoptive transfer BMC BALB/c BALB/c Recipient Donor Lungs Latency Acute phase Episome Virus CD8 T cells 1 5 10 months

  8. The immunodominant IE1 peptide of murine CMV ORF Phase Sequence Restriction Reference m123 (ie1)IE 168YPHFMPTNL176 Ld Reddehase, Rothbard, and Koszinowski, Nature, 1989

  9. TAP IE1 + IFN-g IFN-g Processing and presentation of the IE1 peptide Processing Immuno- proteasome Constitutive proteasome ERAAP ER For a review, see: Reddehase, Nature Rev. Immunol., 2002 Golgi Presentation TCR CD8+ T cell

  10. Enrichment of IE1 peptide-specific CD8 T cells during latency Lungs Latency Acute phase Holtappels et al., J.Virol., 2000 Virus CD8 T cells mo 1 5 10 60.000 5 5 4 4 3 3 % ELISPOT-reactive CD8 T cells % ELISPOT-reactive CD8 T cells 2 2 30.000 1 1 3.000 12.000 m18 M45 M83 M84 m18 M45 M83 M84 m04 m04 m123/IE1 m123/IE1

  11. 1 5 3 2 What is the motor that drives the selective expansion of the IE1-specific CD8 T cells? Major Immediate-Early (MIE) region of mCMV Selective and stochastic IE1 gene expression during latency Signal Receptor ie1/3 transcription unit TF TFBS 5 4 3 2 1 M122 m123 P1/3 enhancer Activation Differential splicing IE1 specific RT-PCR 4 3 2 1 IE1 mRNA IE3 mRNA

  12. 1 5 3 2 What is the motor that drives the selective expansion of the IE1 specific CD8 T cells? Major Immediate-Early (MIE) region of mCMV Selective and stochastic IE1 gene expression during latency Signal Receptor ie1/3 transcription unit TF TFBS 5 4 3 2 1 M122 m123 P1/3 enhancer Activation Differential splicing IE1 specific RT-PCR 4 3 2 1 IE1 mRNA IE3 mRNA

  13. 1 5 3 2 What is the motor that drives the selective expansion of the IE1 specific CD8 T cells? Major Immediate-Early (MIE) region of mCMV Selective and stochastic IE1 gene expression during latency Signal Receptor ie1/3 transcription unit TF TFBS 5 4 3 2 1 M122 m123 P1/3 enhancer Activation Differential splicing IE1 specific RT-PCR 4 3 2 1 IE1 mRNA IE3 mRNA

  14. 1 5 3 2 What is the motor that drives the selective expansion of the IE1 specific CD8 T cells? Major Immediate-Early (MIE) region of mCMV Selective and stochastic IE1 gene expression during latency Signal Receptor ie1/3 transcription unit TF TFBS 5 4 3 2 1 M122 m123 P1/3 enhancer Activation Differential splicing IE1 specific RT-PCR 4 3 2 1 IE1 mRNA IE3 mRNA

  15. 1 5 3 2 What is the motor that drives the selective expansion of the IE1 specific CD8 T cells? Major Immediate-Early (MIE) region of mCMV Selective and stochastic IE1 gene expression during latency Signal Receptor ie1/3 transcription unit TF TFBS 5 4 3 2 1 M122 m123 P1/3 enhancer Activation Differential splicing Poisson distribution analysis of variegated gene expression 4 3 2 1 IE1 mRNA Kurz et al., JVI, 1999 Grzimek et al., JVI, 2001 Simon et al., JVI, 2005 IE3 mRNA

  16. Generation of recombinant CMV with a point mutation in the codon of the C-terminal MHC anchor residue of the IE1 peptide 2 4 3 IE1 N A P T M M P F F T H H GCA N Y Y P P L L176A A176L CTA WT and revertant MHC class-I anchor mutant

  17. ~ ~ Elimination of IE1 antigenicity enhances the frequency of latency-associated IE1 transcription 150 131 105 100 Incidence of IE1 transcription* 84 50 36 27 21 10 Revertant Mutant * 5 lungs Simon et al., in preparation

  18. IE1 Desilencing and immune sensing hypothesis

  19. IE1-specific CD8 T cell Desilencing and immune sensing hypothesis

  20. IE1-specific CD8 T cell IE1 Desilencing and immune sensing hypothesis

  21. IE1-specific CD8 T cell Desilencing and immune sensing hypothesis

  22. IE1-specific CD8 T cell IE1 Desilencing and immune sensing hypothesis

  23. IE1-specific CD8 T cell Effector function Desilencing and immune sensing hypothesis

  24. ~ Multiple checkpoints for immune sensing MIE locus latency Recurrence Stages of transcriptional reactivation IE1 MIE Locus Immunosuppression anti-IE1 anti-X1 anti-Xn Open viral chromatin structure at all essential loci Abrogation of immune sensing by immunosuppression Conditions for virus recurrence:

  25. How could latency-associated CMV gene expression contribute to immune senescence? • Cellular aging of clonotypic memory cells by a high number • of cell divisions • 2. Misallocation of immune system resources by clonal expansion • of memory CD8 T cells specific for a single pathogen

More Related